The invention provides methods for (a) prolonging time to hospitalization for
heart failure; (b) prolonging time to first hospitalization for
heart failure; (c) reducing the total number of days a patient with
heart failure spends in the hospital for heart failure for a single
hospital stay (i.e., reducing the duration of a single
hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits); (g) increasing the
left ventricular ejection fraction in a heart failure patient; (h) treating a
sexual dysfunction (e.g.,
erectile dysfunction and
female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the
quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type
natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering
blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing
patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating
ischemic disease and / or
coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a
hydralazine compound or pharmaceutically acceptable salt thereof, (ii)
isosorbide dinitrate and / or
isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of
angiotensin converting enzyme inhibitors, β-
adrenergic antagonists,
angiotensin II antagonists,
aldosterone antagonists, cardiac glucosides (
digitalis), and
diuretic compounds.